{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:14:21Z","timestamp":1770743661183,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017570","name":"Commonwealth Serum Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017570","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.ahj.2020.04.029","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T21:54:14Z","timestamp":1589579654000},"page":"140-146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["The Second Strategic Reperfusion Early After Myocardial Infarction (STREAM-2) study optimizing pharmacoinvasive reperfusion strategy in older ST-elevation myocardial infarction patients"],"prefix":"10.1016","volume":"226","author":[{"given":"Paul W.","family":"Armstrong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kris","family":"Bogaerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter R.","family":"Sinnaeve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Pages","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Danays","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frans","family":"Van de Werf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2020.04.029_bb0005","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa1301092","article-title":"Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction","volume":"368","author":"Armstrong","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.04.029_bb0010","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1161\/CIRCULATIONAHA.114.009570","article-title":"ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention","volume":"130","author":"Sinnaeve","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2020.04.029_bb0015","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.ahj.2015.03.011","article-title":"Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the STrategic Reperfusion Early after Myocardial infarction trial","volume":"169","author":"Armstrong","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2020.04.029_bb0020","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/eurheartj\/ehr403","article-title":"Safety and efficacy of a pharmaco-invasive reperfusion strategy in rural ST-elevation myocardial infarction patients with expected delays due to long-distance transfers","volume":"33","author":"Larson","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2020.04.029_bb0025","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2020.04.029_bb0030","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1016\/j.jacc.2018.10.012","article-title":"Scaling STEMI Care Internationally: ACC\u2019s Global STEMI Quality Improvement Initiative","volume":"72","author":"Wilson","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2020.04.029_bb0035","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1161\/CIRCULATIONAHA.117.030582","article-title":"Efficacy and safety of a pharmaco-invasive strategy with half-dose alteplase versus primary angioplasty in st-segment-elevation myocardial infarction: EARLY-MYO Trial","volume":"136","author":"Pu","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2020.04.029_bb0040","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.008059","article-title":"Pharmacoinvasive strategy versus primary percutaneous coronary intervention in st-elevation myocardial infarction in clinical practice: insights from the vital heart response registry","volume":"12","author":"Bainey","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2020.04.029_bb0045","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/eurheartj\/ehy004","article-title":"Impact of treatment delay on mortality in ST-segment elevation myocardial infarction (STEMI) patients presenting with and without haemodynamic istability: Results from the German prospective, multicentre FITT-STEMI trial","volume":"39","author":"Scholz","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2020.04.029_bb0050","article-title":"Five-year outcomes following timely primary percutaneous intervention, late primary percutaneous intervention, or a pharmaco-invasive strategy in ST-segment elevation myocardial infarction: the FAST-MI programme","author":"Danchin","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2020.04.029_bb0055","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.amjcard.2014.06.011","article-title":"Outcomes of a pharmacoinvasive strategy for successful versus failed fibrinolysis and primary percutaneous intervention in acute myocardial infarction (from the strategic reperfusion early after myocardial infarction [STREAM] study)","volume":"114","author":"Welsh","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2020.04.029_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjcard.2019.09.044","article-title":"Pharmacoinvasive strategy versus primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in patients \u226570 years of age","volume":"125","author":"Auffret","year":"2020","journal-title":"Am J Cardiol"},{"issue":"21","key":"10.1016\/j.ahj.2020.04.029_bb0065","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1001\/jama.2010.712","article-title":"Association between timeliness of reperfusion therapy and clinical outcomes in ST-elevation myocardial infarction","volume":"303","author":"Lambert","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2020.04.029_bb0070","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.115.003508","article-title":"Pharmacoinvasive strategy versus primary percutaneous coronary intervention in patients with st-segment-elevation myocardial infarction: a propensity score-matched analysis","volume":"9","author":"Sim","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2020.04.029_bb0075","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1016\/j.jcin.2016.07.004","article-title":"Safety and efficacy of a pharmacoinvasive strategy in ST-segment elevation myocardial infarction: a patient population study comparing a pharmacoinvasive strategy with a primary percutaneous coronary intervention strategy within a regional system","volume":"9","author":"Rashid","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2020.04.029_bb0080","article-title":"Primary PCI and the indistinct 120 min time limit","author":"Sinnaeve","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2020.04.029_bb0085","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0140-6736(99)07403-6","article-title":"Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial","volume":"354","author":"Van de Werf","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2020.04.029_bb0090","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0140-6736(01)05775-0","volume":"358","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2020.04.029_bb0095","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/01.CIR.0000081659.72985.A8","volume":"108","author":"Wallentin","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2020.04.029_bb0100","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(06)68147-6","volume":"367","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2020.04.029_bb0105","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ahj.2010.04.007","article-title":"The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study","volume":"160","author":"Armstrong","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2020.04.029_bb0110","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1161\/CIRCULATIONAHA.108.796383","article-title":"Is duration of symptoms is the key modulator of the choice of reperfusion for ST-elevation myocardial infarction","volume":"119","author":"Armstrong","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2020.04.029_bb0115","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1136\/heartjnl-2014-306686","article-title":"Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged","volume":"101","author":"Gershlick","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.ahj.2020.04.029_bb0120","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1161\/STROKEAHA.118.022606","volume":"50","author":"Powers","year":"2019","journal-title":"Stroke"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870320301459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870320301459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:58:06Z","timestamp":1762077486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870320301459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":24,"alternative-id":["S0002870320301459"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2020.04.029","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Second Strategic Reperfusion Early After Myocardial Infarction (STREAM-2) study optimizing pharmacoinvasive reperfusion strategy in older ST-elevation myocardial infarction patients","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2020.04.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}